• Acridine Orange hydrochloride Protocol Guide

  2026-08-31

  Acridine Orange hydrochloride is a membrane-permeable fluorescent nucleic acid dye for differential DNA and RNA or single-stranded nucleic acid staining in cytochemical and flow-based workflows. It is suitable for cell cycle analysis, apoptosis detection, and nucleic acid profiling, but should not be selected for non-nucleic-acid targets or protocols requiring long-term storage of prepared solutions.

• SGC-CBP30 for Reliable Cell Assays

  2026-08-31

  Learn how SGC-CBP30 (SKU A4491), a selective CREBBP/EP300 bromodomain inhibitor, can be incorporated into viability, proliferation, and cytotoxicity workflows. This scenario-based guide connects biochemical potency, practical formulation, storage, and lung adenocarcinoma research without confusing mechanistic perturbation with a universal assay control.

• Estradiol, ER Stress, and CD4+ T-Cell Recovery

  2026-08-30

  This reference study shows that estradiol restores splenic CD4+ T-lymphocyte function after hemorrhagic shock by engaging ERα and GPR30 while suppressing endoplasmic reticulum stress. Its receptor-selective pharmacology provides a useful framework for distinguishing classical and non-genomic estrogen signaling in post-shock immune dysfunction.

• Z-VAD-FMK: Mapping Cell-Death Decisions

  2026-08-29

  A mechanistic and translational guide to using Z-VAD-FMK to distinguish caspase-dependent apoptosis from inflammatory and necroptotic cell death, with practical considerations for experimental design.

• Azilsartan Medoxomil: Sustained AT1 Blockade

  2026-08-28

  The 2017 mini-review linked azilsartan medoxomil’s persistent AT1-receptor interaction with its pharmacokinetic profile, blood-pressure efficacy, and tolerability relative to established ARBs. Its central contribution is a translational interpretation of receptor-binding and clinical evidence, while also emphasizing that improved blood-pressure control has not yet been conclusively tied to lower mortality.

• QRICH1–HMGB1 Signaling in HBV Fibrosis

  2026-08-28

  A 2025 Immunobiology study identifies QRICH1 as an endoplasmic reticulum stress effector that amplifies HBV-associated HMGB1 translocation and secretion in hepatocytes. The work connects QRICH1-dependent transcriptional regulation with SIRT6-linked HMGB1 acetylation, providing a mechanistic framework for understanding inflammatory progression toward hepatic fibrosis.

• (+)-Bicuculline: Practical Lab Protocol

  2026-08-27

  This guide explains how to prepare, store, and quality-control (+)-Bicuculline for experiments involving GABAA receptor antagonism, GABAergic signaling pathway analysis, and related neuronal assays. It is intended as a research-use workflow aid, not as clinical guidance, and product-specific observations should not be generalized beyond the stated models.

• Cisplatin as a DNA-Repair Stress Test

  2026-08-27

  Cisplatin (CDDP) is more than a cytotoxic endpoint: it can function as a controlled stress test of DNA repair competence. This article translates recent nasopharyngeal carcinoma findings into practical assay design, orthogonal readouts, and model-selection principles.

• HOXC8, Caspase-1, and NSCLC Pyroptosis

  2026-08-26

  The reference study identifies HOXC8 as a transcriptional suppressor of CASP1 that protects non-small cell lung carcinoma cells from caspase-1-dependent pyroptosis. Its central innovation is linking HOXC8 to HDAC1/2 recruitment at the CASP1 promoter, establishing an epigenetic mechanism that connects tumor-cell survival with inflammatory cell-death control.

• CDK9 inhibitor (A3294): Protocol and QC Guide

  2026-08-26

  CDK9 inhibitor (A3294) is a selective serine/threonine kinase inhibitor for investigating CDK9-dependent transcription elongation and HIV-1 propagation in defined research assays. It is not intended for broad-spectrum CDK inhibition, generalized cytotoxicity studies, or experiments requiring long-term storage of prepared solutions.

• Apicidin Workflows for HDAC and Oocyte Assays

  2026-08-25

  Apicidin is a histone deacetylase inhibitor that connects HDAC3/6-focused epigenetic studies with cancer, angiogenesis, and reproductive-toxicology workflows. This guide translates its biochemical profile into practical formulation, assay, optimization, and troubleshooting decisions.

• iMSC Exosomes Reprogram Macrophages in Disc Degeneration

  2026-08-25

  This 2025 Advanced Science study identifies a reciprocal inflammatory circuit between senescent nucleus pulposus cells and macrophages in intervertebral disc degeneration. It shows that exosomes from human iPSC-derived mesenchymal stem cells deliver miR-100-5p, suppress mTORC1-associated glycolytic programming, and promote a shift from inflammatory M1 macrophages toward reparative M2 phenotypes.

• (R)-MG132: A Better Test of Proteasome Causality

  2026-08-24

  Translational studies often attribute protein stabilization or metabolic rewiring to proteasome inhibition without proving on-target causality. This guide explains how (R)-MG132, the MG-132 enantiomer with markedly reduced proteasome activity, can strengthen ubiquitin-proteasome system research and clarify HNRNPU–PHGDH mechanisms in cervical cancer.

• 11β-HSD1, Notch, and NK Cells in Liver Fibrosis

  2026-08-24

  A 2025 study identifies a dual immunometabolic mechanism by which 11β-HSD1 inhibition attenuates experimental liver fibrosis: reduced intracellular cortisol suppresses hepatic stellate-cell activation, while Notch pathway inhibition and enhanced natural killer-cell responses support clearance of activated stellate cells. The findings expand liver fibrosis research beyond metabolic regulation alone and provide a framework for evaluating enzyme, pathway, and immune-cell readouts together.

• Ionomycin calcium salt: Calcium Signaling Workflows

  2026-08-23

  Ionomycin calcium salt provides a rapid, controllable way to elevate intracellular Ca2+ for imaging, secretion, protein-synthesis, and apoptosis experiments. This workflow positions the calcium ionophore as a mechanistic control for STIM1-linked cancer biology while separating useful assay evidence from therapeutic claims.

8565 records 1/571 page Next 12345 下5页 Last page